Literature DB >> 2639662

Impact of ketoconazole on the metabolism of prednisolone.

R M Zürcher1, B M Frey, F J Frey.   

Abstract

The impact of ketoconazole (200 mg for 7 days) on the kinetics of oral prednisone and intravenous prednisolone and on the apparent activity of the 6 beta-hydroxylase was investigated in 10 healthy volunteers. The ratio of urinary 6 beta-OH-cortisol/17-OH-corticosteroids declined by greater than 50% and the urinary excretion of 6 beta-OH-prednisolone decreased more than twofold in all subjects. The decline of the activity of the 6 beta-hydroxylase was associated with impaired metabolic and renal clearances of total and unbound prednisolone. The ratios of the AUCs of prednisolone/prednisone after oral prednisone and intravenous prednisolone were independent of the administration of ketoconazole, suggesting that the enzymes responsible for the interconversion of prednisolone in equilibrium prednisone were not affected by ketoconazole. Thus ketoconazole inhibits 6 beta-hydroxylase and increases the exposure of the body to the biologically active unbound prednisolone after oral prednisone or intravenous prednisolone.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2639662     DOI: 10.1038/clpt.1989.42

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  17 in total

Review 1.  Adverse drug reactions to systemic antifungals. Prevention and management.

Authors:  J R Perfect; M H Lindsay; R H Drew
Journal:  Drug Saf       Date:  1992 Sep-Oct       Impact factor: 5.606

2.  [Use-risk consideration of anti-infective agents from the point of view of the licensing authority].

Authors:  W Christ; B Esch
Journal:  Infection       Date:  1991       Impact factor: 3.553

Review 3.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

4.  Pharmacokinetics of total and unbound prednisone and prednisolone in stable kidney transplant recipients with diabetes mellitus.

Authors:  Ileana A Ionita; Ken Ogasawara; Reginald Y Gohh; Fatemeh Akhlaghi
Journal:  Ther Drug Monit       Date:  2014-08       Impact factor: 3.681

Review 5.  Clinical pharmacokinetics of prednisone and prednisolone.

Authors:  B M Frey; F J Frey
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

6.  Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats.

Authors:  G M Ferron; N A Pyszczynski; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1999-02

Review 7.  The clinical and economic potential of cyclosporin drug interactions.

Authors:  J E Martin; A J Daoud; T J Schroeder; M R First
Journal:  Pharmacoeconomics       Date:  1999-04       Impact factor: 4.981

Review 8.  The use of other drugs to allow a lower dosage of cyclosporin to be used. Therapeutic and pharmacoeconomic considerations.

Authors:  T E Jones
Journal:  Clin Pharmacokinet       Date:  1997-05       Impact factor: 6.447

Review 9.  Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data.

Authors:  J A P Da Silva; J W G Jacobs; J R Kirwan; M Boers; K G Saag; L B S Inês; E J P de Koning; F Buttgereit; M Cutolo; H Capell; R Rau; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2005-08-17       Impact factor: 19.103

Review 10.  Endemic Mycoses in Solid Organ Transplant Recipients.

Authors:  Jeremy S Nel; Luther A Bartelt; David van Duin; Anne M Lachiewicz
Journal:  Infect Dis Clin North Am       Date:  2018-09       Impact factor: 5.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.